Ind-Swift Laboratories Approves Audited FY26 Financial Results and Reappoints Cost Auditors
Ind-Swift Laboratories Limited's Board approved audited standalone and consolidated financial results for Q4 and FY26 ended March 31, 2026. M/s. V. Kumar & Associates were re-appointed as Cost Auditors for FY27. The company issued 1.80 crore equity shares from warrant conversion and ESOPs.
Approval of financial results and re-appointment of auditors are routine but important corporate actions that provide clarity to stakeholders.
The company has approved its audited financial results and reappointed its cost auditors, indicating operational continuity and compliance.
Ind-Swift Laboratories Limited announced the outcome of its Board Meeting held on May 28, 2026. The Board has approved the audited financial results for the fourth quarter and the financial year ended March 31, 2026, on both standalone and consolidated bases. These results include the Statement of Profit & Loss, Statement of Assets & Liabilities, and Statement of Cash Flow, along with the Auditors' Reports. The company has made arrangements for the publication of these financial results in newspapers as per SEBI regulations. Additionally, the Board approved the re-appointment of M/s. V. Kumar & Associates as the Cost Auditors for the financial year 2026-27. The Board Meeting commenced at 5:00 PM and concluded at 6:00 PM.
The accompanying auditor's reports for both standalone and consolidated results, issued by M/s. Rattan Kaur & Associates, confirm that the financial results are presented in accordance with SEBI regulations and provide a true and fair view. The reports highlight the issuance of 1,80,93,000 equity shares during the year due to the conversion of share warrants and under the Employee Stock Option Plan. The auditors also drew attention to the agreement to sell Land and Building of Unit-IV, Baddi, with Rs. 1710 Lakhs received as part of the sale consideration and a balance of Rs. 110 Lakhs pending receipt.
The standalone financial statements as of March 31, 2026, show total assets of ₹1,65,434.16 Lakhs and total equity of ₹1,37,069.72 Lakhs. The cash flow statement indicates a net cash flow from operating activities of ₹16,015.37 Lakhs for the year ended March 31, 2026. The consolidated financial results also include the financial information of several subsidiaries and joint ventures.
What to do with a filing like this
Ind-Swift Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Ind-Swift Laboratories Limited. Read the original for the full detail.